Gene Therapy:

Intellectual Property

uniQure has a leading intellectual property portfolio related to AAV gene therapy.

The following partial list identifies uniQure’s rights in U.S. patents associated with our technology and manufacturing.   

FIX-Padua (Factor IX protein with a leucine at the R338 position)
Simioni
First Filing date: Sept. 15, 2009
U.S. Patent No. 9,249,405

Improved AAV Vectors Produced in Insect Cells
Urabe et al.
First Filing date: Oct. 19, 2006
U.S. Patent No. 8,163,543 (B2)

Vectors with modified initiation codon for the translation of AAV-REP78 useful for production of AAV in insect cells
Hermens et al.
First Filing date: Jun. 20, 2007
U.S. Patent No. 8,512,981 (B2)
U.S. Patent No. 8,952,144 (B2)
U.S. Patent No. 9,708,627 (B2)
U.S. Patent Application No. 15/424,560 (pending) 

Baculoviral vectors comprising repeated coding sequences with differential codon biases
Bakker and Hermens
First Filing date: July 25, 2008
U.S. Patent No. 8,697,417(B2)
U.S. Patent No. 9,580,691 (B2)
U.S. Patent Application No. 14/870,614 (pending)

Optimization of expression of parvoviral rep and cap proteins in insect cells
Bakker et al.
First Filing date: Feb. 19, 2009
U.S. Patent No. 8,642,314 (B2)
U.S. Patent No. 9,260,724 (B2)

Removal of contaminating viruses from AAV preparations
Hermens and Smith
First Filing date: Sep. 07, 2012
U.S. Patent Application No. 14/343,884

Mutated Rep encoding sequences for use in AAV production
Noordman and Bakker
First Filing date: Mar. 11, 2011
U.S. Patent No. 9,228,174 (B2)
U.S. Patent Application No. 14/952,303

DNA Impurities in a Composition Comprising a Parvoviral Virion
Lubelski and Hermens
First Filing date: Nov. 27, 2015
U.S. Patent Application No. 15/531,095 (WO2016083560)

Further improved AAV vectors produced in insect cells
Lubelski et al.
First Filing date: Mar. 10, 2015
U.S. Patent Application No. 15/124,139 (WO2015137802)

 

Disclaimer: The information presented reflects the status as of July 2017. This overview, comprising a selection from issued and pending patents, is not intended to be a complete description of the applicable technology, and is qualified by reference to the full text of the patents as available at the USPTO and other related documentation. With regard to the overview, given its nature, one should not place undue reliance thereon, and we assume no obligation to update this overview, even if new information becomes available in the future.